Protalix BioTherapeutics to Host Investor Day on Fabry Disease and Gout Treatments

Protalix BioTherapeutics, Inc., a biopharmaceutical firm specializing in the development and commercialization of therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx®, will host an in-person investor day on June 26, 2024, at the Lotte Palace New York Hotel in New York. The event will commence at 8:30 a.m. EDT.

The investor day will feature presentations from notable experts in the medical field. Aleš Linhart, DSc, FESC, from Charles University in Prague, will provide insights into the current treatment landscape for Fabry disease and discuss Elfabrio® (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant α-Galactosidase-A enzyme approved for adult patients with Fabry disease. Naomi Schlesinger, MD, of the University of Utah, will address the treatment landscape for uncontrolled gout and share top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX-115, a plant cell-expressed recombinant PEGylated uricase.

Additionally, Protalix's President and CEO, Dror Bashan, will deliver a corporate overview and outline the company’s strategic vision. The formal presentations will be followed by a live question-and-answer session.

Aleš Linhart, an esteemed cardiologist, heads the Department of Cardiovascular Medicine at the First Medical Faculty and General University in Prague. He also serves as vice-dean for international affairs at Charles University. Linhart's research largely focuses on Fabry disease, metabolic cardiomyopathies, noninvasive cardiac imaging, and atherosclerosis. He has authored or co-authored over 450 scientific papers, 85 book chapters, and three monographs. He is a member of several scientific societies, including the Czech and European Society of Cardiology (ESC), and has held significant positions such as chairman of the ESC's Working Group on Myocardial and Pericardial Diseases and president of the Czech Society of Cardiology.

Naomi Schlesinger, MD, holds the Harold J, Ardella T, and Helen T Stevenson Presidential Endowed Chair of Rheumatology at the University of Utah. She has previously served as the Chief of the Division of Rheumatology at Rutgers-Robert Wood Johnson Medical School and directed its Gout Center. Notably, Schlesinger has been recognized by the Arthritis Foundation - NJ Chapter as the 2015 Rheumatologist of the Year. Her research in gout has gained wide recognition and includes pioneering work on the efficacy of canakinumab in preventing flares in gout patients, the relationship between gout and erectile dysfunction, and innovative treatments for gout flares.

Protalix BioTherapeutics, headquartered in Carmiel, Israel, is renowned for being the first company to receive FDA approval for a plant cell-based protein produced via its ProCellEx system. Protalix's product, Elfabrio®, has also been approved by the European Medicines Agency. The company has collaborations with Pfizer Inc. for the global development and commercialization of taliglucerase alfa for Gaucher disease, and with Chiesi Farmaceutici S.p.A. for Elfabrio. Protalix’s pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, among other proprietary therapeutic proteins targeting established pharmaceutical markets.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!